γδ T cells predict outcome in zoledronate-treated breast cancer patients

Oncologist

Volumn 18, Issue 8, 2013, Pages

  Welton, Joanne L ^a   Martí, Salvador ^a   Mahdi, Mohammed H ^b   Boobier, Clare ^b   Barrett Lee, Peter J ^a,b   Eberl, Matthias ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b VELINDRE CANCER CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DENOSUMAB; ZOLEDRONIC ACID;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CELL MEDIATED CYTOTOXICITY; GAMMA DELTA T LYMPHOCYTE; HUMAN; LETTER; MEMORY T LYMPHOCYTE; META ANALYSIS (TOPIC); MULTIPLE CYCLE TREATMENT; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME;

BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DIPHOSPHONATES; FEMALE; HUMANS; IMIDAZOLES;

EID: 84883248813     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2013-0097     Document Type: Letter

References (9)

1. Valachis A, Polyzos NP, Coleman RE et al. Adjuvant therapy with zoledronic acid in patients with breast cancer: A systematic review and meta-analysis. The Oncologist 2013;18:353-361.
2. Huang WW, Huang C, Liu J et al. Zoledronic acid as an adjuvant therapy in patients with breast cancer: A systematic review and meta-analysis. PLoS One 2012;7:e40783.
3. Yan T, Yin W, Zhou Q et al. The efficacy of zoledronic acid in breast cancer adjuvant therapy: A meta-analysis of randomised controlled trials. Eur J Cancer 2012;48:187-195.
4. Gnant M. Adjuvant bisphosphonates: A new standard of care? Curr Opin Oncol 2012;24:635-642.
5. Kunzmann V, Wilhelm M. Adjuvant zoledronic acid for breast cancer:Mechanismof action? Lancet Oncol 2011;12:991-992.
6. Fournié JJ, Sicard H, Poupot M et al. What lessons can be learned from γδ T cell-based cancer immunotherapy trials? Cell Mol Immunol 2013;10: 35-41.
7. Meraviglia S, Eberl M, Vermijlen D et al. In vivo manipulation of Vγ9Vδ2 T cells with zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast cancer patients. Clin Exp Immunol 2010;161:290-297.
8. Santini D, Martini F, Fratto ME et al. In vivo effects of zoledronic acid on peripheral γδ T lymphocytes in early breast cancer patients. Cancer Immunol Immunother 2009;58:31-38.
9. Welton JL, Morgan MP, Martí S et al. Monocytes and γδ T cells control the acute-phase response to intravenous zoledronate: Insights from a phase IV safety trial. J Bone Miner Res 2013;28:464-471.